Ardor Drugs Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 23-10-2024
- Paid Up Capital ₹ 4.00 M
as on 23-10-2024
- Company Age 25 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.66 Cr
as on 23-10-2024
- Satisfied Charges ₹ 8.00 M
as on 23-10-2024
- Revenue 40.29%
(FY 2023)
- Profit -10.18%
(FY 2023)
- Ebitda 14.07%
(FY 2023)
- Net Worth 17.60%
(FY 2023)
- Total Assets 18.83%
(FY 2023)
About Ardor Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹5.66 Cr. The company has closed loans amounting to ₹8.00 M, as per Ministry of Corporate Affairs (MCA) records.
Munna Kushwaha and Harshal Desai serve as directors at the Company.
- CIN/LLPIN
U24231GJ1999PTC036199
- Company No.
036199
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 1999
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ardor Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Munna Kushwaha  | Director | 23-Aug-2021 | Current |
| Harshal Desai | Director | 13-Nov-2019 | Current |
Financial Performance of Ardor Drugs.
Ardor Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.29% increase. The company also saw a substantial fall in profitability, with a 10.18% decrease in profit. The company's net worth Soared by an impressive increase of 17.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ardor Drugs?
Unlock access to Ardor Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Sep 2022 | ₹1.00 Cr | Open |
Others Creation Date: 08 Sep 2022 | ₹1.00 Cr | Open |
Others Creation Date: 07 Sep 2022 | ₹5.00 M | Open |
How Many Employees Work at Ardor Drugs?
Ardor Drugs has a workforce of 10 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ardor Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ardor Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
